Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties
One in two women with advanced ovarian cancer has an HRD-positive tumor
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Lenalidomide is used to treat various types of cancers.
The ANDA was filed as 'First to File' submission on NCE-1 date.
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Subscribe To Our Newsletter & Stay Updated